From chemical biology parlor trick to clinical success story: the story of PROTACS
PROTACs have rapidly progressed from being an intrigue of cell biology to a key player in drug discovery – in particular, for disease-causing proteins previously thought to be undruggable. What’s their story? Originally seen as a chemical biology ‘parlor trick’, it fell to a small biotech to blaze the trail and prove the potential of PROTACs for drugging the undruggable. Here, we speak to Ian Taylor, Chief Scientific Officer of Arvinas (CT, USA), about the science behind PROTACs, and how Arvinas overcame skepticism, taking PROTACs from the lab to the clinic for the first time. Please tell us about yourself...
To view this content, please register now for access
Join our member community for FREE to access a collection of journal and online-only features, including:
- Exclusive access to educational videos, eBooks and insights into top BioTechniques journal articles
- The latest news and journal updates delivered straight to your inbox when you want it
- Personalized recommendations for the latest member-exclusive podcasts, interviews and expert opinions
- Priority registration to webinars, panel discussions and events
- Access to competitions and journal publication discounts, including 10% off open access fees when you sign up today!
